• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • Understanding ALS/MND
    • What is ALS/MND
    • Genetics
    • Diagnosis
    • Glossary
    • Navigating the Community
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Clinical Trial Registry Accuracy and Maintenance in ALS/MND Research
      • Open Science
        • Open Label Extension
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven Treatments
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition, Swallowing and Saliva
      • Activities of Daily Living and Occupational Therapy
      • Muscles, Mobility and Exercise
      • Respiratory Care
      • Speech and Communication
      • Voice Preservation
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • Masitinib
      • NurOwn
      • CNM-Au8
      • ILB
      • AstroRx
      • Neuronata-R / Lenzumestrocel
      • PrimeC
      • NP001
      • Pridopidine
      • SOD1 Therapies and Trials
      • C9orf72 Therapies and Trials
      • SPG302
      • Regulatory T Cell Enhancing Therapies
      • Ulefnersen
    • Approved Drugs
      • Nuedexta
      • Radicava / Edaravone
      • Riluzole / Tiglutik
      • Rozebalamin / Methylcobalamin
      • Tofersen / Qalsody
    • Drugs No Longer in Development
      • AMX0035
      • Reldesemtiv
      • Arimoclomol
      • TUDCA
      • CuATSM
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • R.A.C.E. to Diagnose ALS/MND
  • Programs & Events
    • Calendar of Events
    • Global Day Calendar
    • Alliance Meeting
    • Allied Professionals Forum
    • “Day in the Life Of” Suite
    • Alliance Webinars
    • ALS/MND Connect
    • March of Faces
    • Patient Fellows Program
    • Alliance Fellows
    • SEED Grant Program
    • Awards
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
      • Student Innovation Award
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Councils, Forums & Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Newsletter Archive
  • Members
    • Member Registration
    • Forgot Password

Drugs in Development

To test new drugs and treatments for ALS/MND, researchers and pharmaceutical companies must perform clinical trials. A clinical trial is a therapeutic or observational research study to test whether a new drug or therapy is safe and effective for use in humans. Prior to any clinical trial, a drug must pass through a series of steps. 

For ALS/MND, there are many potential drugs and therapies currently undergoing clinical trials. Clinical trials are essential to new drug approvals. However, enrollment in a clinical trial should always be voluntary. People living with ALS/MND must consent prior to enrollment and have the right to know all pertinent details surrounding the trial.

Clinical Trial Information

Here are links to databases of known clinical trials for ALS/MND.

  • ALS/MND Clinical Trial Navigator: The ALS Therapy Development Institute created the ALS Trial Navigator is a comprehensive resource for making informed decisions about participating in ALS/MND clinical trials. Use this innovative tool learn about clinical trials and get a personalized list of ALS/MND trials based on your eligibility and preferences. (Language: English)
  • ALS International Clinical Trial Database: The Associazione conSLAncio Onlus created the ALS/MND International Clinical Trial Database. Built on a multi-lingual website, this features users to view the current status of clinical trials taking place at sites in, or close to, Italy. Each trial is linked to the official trial registry where users can directly access study objectives, eligibility criteria and study contacts. (Language: Italian)
  • HEALEY ALS Platform Trial: The HEALEY ALS Platform Trial aims to accelerate the process of drug development and the path for effective treatment for ALS/MND by testing multiple drugs simultaneously and adaptively. This design has been seen to be successful in cancer trials. Participants will have an equal chance to be randomized to all regimens that are active at the time of screening. Once randomized to a regimen, participants will be randomized to receive either the study drug or placebo. New regimens will be continuously added as new investigational products become available. The trial is recruiting in the United States only and will enroll additional participants as each new regimen is available. (Language: English)

Information on Drugs in Clinical Trial

Here are briefing notes from the International Alliance’s Scientific Advisory Council on drugs and therapies currently being researched.

SPG302

Masitinib

Pridopidine

NP001

Neuronata-R / Lenzumestrocel

Ulefnersen

NurOwn

CNM-Au8

AstroRx

ILB

PrimeC

SOD1-Targeted Therapies & Trials

Regulatory T Cell Enhancing Therapies

C9orf72 Therapies and Trials

Primary Sidebar

Drugs in Development

  • AB Science – Masitinib
  • NurOwn
  • Clene Nanomedicine – CNM-Au8
  • ILB
  • Kadimastem – AstroRx
  • Neuronata-R / Lenzumestrocel
  • NeuroSense – PrimeC
  • NP001
  • Prilenia Therapeutics – Pridopidine
  • SOD1 Therapies & Trials
  • SPG302
  • Regulatory T Cell Enhancing Therapies
  • Ulefnersen

  • Luis Antonio Pimenta Lima, Brazil

    Luis Antonio Pimenta Lima, Brazil

  • Mauril Bélanger, Canada

    Mauril Bélanger, Canada

  • Sharon Corosanite, USA

    Sharon Corosanite, USA

  • Danny Reviers, Belgium

    Danny Reviers, Belgium
    DannyReviers

  • Cath Muir, UK

    Cath Muir, UK
    Cath

  • Maurice LeClerc, Canada

    Maurice LeClerc, Canada

  • Lineke Veenstra, Netherlands

    Lineke Veenstra, Netherlands

  • Sébastien Batiot, France

    Sébastien Batiot, France

  • Chirag Walia, India

    Chirag Walia, India
    ChiragWalia

  • Rosie Riley, USA

    Rosie Riley, USA

  • Elisabeth Zahnd, Switzerland

    Elisabeth Zahnd, Switzerland

  • Ian Gale, Australia

    Ian Gale, Australia

  • Brigitte Wernli, Switzerland

    Brigitte Wernli, Switzerland

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Duncan Bayly, Australia

    Duncan Bayly, Australia

  • João Marcos Andrietta, Brazil

    João Marcos Andrietta, Brazil

  • Mauril Belanger, Canada

    Mauril Belanger, Canada

  • Ann Nicol, USA

    Ann Nicol, USA

  • Roxana Canova, Argentina

    Roxana Canova, Argentina

  • Malcolm Buck, Australia

    Malcolm Buck, Australia

  • Yessenia Hernandez Mendoza, Mexico

    Yessenia Hernandez Mendoza, Mexico

  • Rudiger Hanemann, Germany

    Rudiger Hanemann, Germany

  • Irene McCaughey, Australia

    Irene McCaughey, Australia

  • Jette Odgaard Villemoes, Denmark

    Jette Odgaard Villemoes, Denmark

  • PALS and CALS, Singapore

    PALS and CALS, Singapore

  • Fabio Carvalho, Brazil

    Fabio Carvalho, Brazil

  • Michael Lee, Australia

    Michael Lee, Australia

  • Glen Elison, USA

    Glen Elison, USA

  • Susan Anderson, USA

    Susan Anderson, USA

  • Olga, Argentina

    Olga, Argentina

  • Joyce Rusinak, USA

    Joyce Rusinak, USA

  • Carlos Alberto Arango, Colombia

    Carlos Alberto Arango, Colombia

  • Andres Estevez Guersznik, Ireland

    Andres Estevez Guersznik, Ireland

  • Federica Mastrosimone, Italy

    Federica Mastrosimone, Italy

  • Maria Santos Garcia Tellez, Mexico

    Maria Santos Garcia Tellez, Mexico

  • Kirsty Gerlach, New Zealand

    Kirsty Gerlach, New Zealand

  • Eric Von Schaumburg, USA

    Eric Von Schaumburg, USA

  • Andrea Zicchieri, Italy

    Andrea Zicchieri, Italy
    AndreaZicchieri_conSLAncioItaly

  • Jeff Sutherland, Canada

    Jeff Sutherland, Canada
    jspic

  • Verónica Isabel Castro Molina, Argentina

    Verónica Isabel Castro Molina, Argentina

  • Liong Ting Ngu, Malaysia

    Liong Ting Ngu, Malaysia

  • Bjarne Hytjanstorp, Norway

    Bjarne Hytjanstorp, Norway

  • Claire Garry, USA

    Claire Garry, USA
    20200117_214643

  • Fabrice Kamp, Germany

    Fabrice Kamp, Germany

  • Yannick Richard, Canada

    Yannick Richard, Canada
    yannickrichard

  • Olga Cosentino, Argentina

    Olga Cosentino, Argentina

  • Robbie Caliste, UK

    Robbie Caliste, UK

  • Jo Knowlton, Scotland

    Jo Knowlton, Scotland

  • Liz Ogg, Scotland

    Liz Ogg, Scotland

  • Diana Fernandez, Argentina

    Diana Fernandez, Argentina

Learn more about the March of Faces

Footer

Stay connected to the global ALS/MND community.

Subscribe to receive our newsletter and updates on how to get involved across the Alliance network.

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2026 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login